Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.81 |
| ▸ | ITGAV | P06756 | 11/20 | 0.81 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.81 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.81 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.81 |
| ▸ | PPARD | Q03181 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038106 | 1.00 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7168524 | 0.91 | ITGB3 (0.80) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7170852 | 0.91 | ITGB3 (0.80) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7172016 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7037993 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7170011 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7451419 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7168382 | 0.90 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL6657173 | 0.90 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL244383 | 0.90 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576643-B2 | Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation | SMITHKLINE BEECHAM CORPORATION | 2003-06-10 | — | — | US | claimed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | claimed |
| EP-1025090-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | claimed |
| EP-1025090-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2000-08-09 | — | — | EP | claimed |
| WO-1999015508-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | claimed |
| US-6576643-B2 | Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation | SMITHKLINE BEECHAM CORPORATION | 2003-06-10 | — | — | US | disclosed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091264-A1 | Vitronectin receptor antagonists | CALCR, ADGRF1, CALCRL | ITGB3 153/4885ITGAV 168/4885ITGA2B 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.